1.
Smith KS, Rudolph U. Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. Neuropharmacology. 2012 Jan;62(1):54–62.
2.
Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Molecular Psychiatry. 2011 Apr;16(4):383–406.
3.
Balon R. Mood, anxiety, and physical illness: body and mind, or mind and body? Depression and Anxiety. 2006;23(6):377–87.
4.
Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depression and Anxiety. 2007;24(7):495–517.
5.
Cryan JF, Kaupmann K. Don’t worry ‘B’ happy!: a role for GABAB receptors in anxiety and depression. Trends in Pharmacological Sciences. 2005 Jan;26(1):36–43.
6.
Holmes A, Heilig M, Rupniak NMJ, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences. 2003 Nov;24(11):580–8.
7.
Levine J, Cole DP, Chengappa KNR, M.D. SG. Anxiety disorders and major depression, together or apart. Depression and Anxiety. 2001;14(2):94–104.
8.
Freund TF. Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends in Neurosciences. 2003 Sep;26(9):489–95.
9.
Strange PG. Brain biochemistry and brain disorders. Oxford: Oxford University Press; 1992.
10.
Carvalho AF, Van Bockstaele EJ. Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 Jul;38(1):59–67.
11.
Atwood BK, Straiker A, Mackie K. CB2: Therapeutic target-in-waiting. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 Jul;38(1):16–20.
12.
Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics. 2012 Jan;133(1):79–97.
13.
Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy [Internet]. Available from: https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf
14.
H. Attarian OA. Treatment of disorders of hypersomnolence. 16(9):302–302. Available from: http://download.springer.com/static/pdf/61/art%253A10.1007%252Fs11940-014-0302-9.pdf?auth66=1414068132_049751e80fe3aa485ba574ca1df01580&ext=.pdf
15.
N.P. Robertson KJP. Narcolepsy: environment, genes and treatment. 2014;261(8):1644–6. Available from: http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s00415-014-7435-3/fulltext.html
16.
Cera N, Tartaro A, Sensi SL. Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE. 2014 Sep 19;9(9).
17.
Saper CB, Scammell TE. Emerging therapeutics in sleep. Annals of Neurology. 2013 Aug;74(3):435–40.
18.
Eric J. Olson KR. Management of common sleep disorders. 2013;88(4):231–8. Available from: http://www.aafp.org/afp/2013/0815/p231.pdf
19.
Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides. 2013 Dec;47(6):477–88.
20.
Carlos H. Schenck MWM. Insights from studying human sleep disorders. 2005;437(7063):1279–85. Available from: http://www.nature.com.libproxy.ucl.ac.uk/nature/journal/v437/n7063/pdf/nature04287.pdf
21.
Stores G. Medication for sleep-wake disorders. Archives of Disease in Childhood. 2003 Oct 1;88(10):899–903.
22.
Kilduff TS, Peyron C. The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. Trends in Neurosciences. 2000 Aug;23(8):359–65.
23.
Brisbare-Roch C. Promotion of sleep by targeting the orexin system in rats, dogs and humans. 2007;13(2):150–5. Available from: http://www.nature.com.libproxy.ucl.ac.uk/nm/journal/v13/n2/pdf/nm1544.pdf
24.
Mark W. Mahowald MD. Pathophysiologic mechanisms in REM sleep behavior disorder. Current Neurology and Neuroscience Reports [Internet]. 2007 Mar 1;7(Issue 2):167–72. Available from: http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s11910-007-0013-7
25.
Mahowald MW, Schenck CH. Dissociated states of wakefulness and sleep. Neurology [Internet]. 1992;42 Suppl. 6:44–52. Available from: http://ovidsp.uk.ovid.com/sp-3.29.1a/ovidweb.cgi?QS2=434f4e1a73d37e8cfb45f8f3b30e414ee9c0a99335d397e159343d518000931b3c02776b3f73d5a73a4476c2679e970eef9ae15361c4ac577ac7741a1d63634ffba5cef7d6361f976830f426efde734282833d172499d85065998d528dfa9b0a1521d75a5793939995cf8636d6af8a033f8955aa9e537d33ba711609a51d940e69485e1ed697cf1dadc84e2eb68e50c7e93be01be19eed6df41603840c5460e69cc207bc2ddbc6eb8c2189f3a42a831e6ad6a1f92d7fa7471c844690e98333819a6b31708033f7fb585a0e12b8a8ff8a4b15631fb49b82364902e6f027e3eebcba970b2989190824afdb921b41b4cbf09a5f9664093d267e01ea7087c5e48493339b1f5c17aed68251a3a1acd20e242d6f05b7bf22829494401b04044f2cd3299f2879d54f2227f13dbe1ffabb7a65b8acf2bc24807530aa2899ef11384d1b4fbf3817896b409736f1feff76969f4975dfd6acee872cc4ce58ece4230f9c54637f8d18eaeecc4549cc0232c603e2ea279491d13f5967cebd4198c980bbc1a1961c9fb6c6a0fde681623ad04596ddbbaf176fb8f0d3f6c5386b4c157100ac152faa593a4b30ee7c81a0ee1516e1d34e177784cbff5d9006d96104cafddee1e63954dadefd1c715cd30ff8a211ea85de27b7fdc64f03196bd4290f40feb440651d59a0e1b6648c400dad2f5376ab1ce4784f82bcaad740549b509b2029051d56786abcf251cfd30f26efaebb17497d7921b9cdeb08ba50116dbcb2fcae875d0c5bde55c8fa09c1f7f7193df678717538a52e4bbed2d39531859aaca89289746844991df79533fbd7fe89abf1d56813ec076e4e4b61889d4e44eaf024b1319d95f40dbae788f62a09ee651249ae9c6e29f96e1b27c22ed5bb1fa707cdbf233c5ee219ae76b7c8619a584f5de1974a6bc60f759332351a3004ae5a1394c48613a2f8b2295083bf4f2ee4bda9c40f34d389ec6e7cc1bfdcb003f10dd9c42068aa6f3fe28f579fe4f88904185eda4f190c8964edaaf5b28c7a4f7e5f403a33c1d53baed312e42693f7a1e0
